- Transgenomic (TBIO -4%) launches its CMT NGS Panel for the diagnosis of Charcot-Marie-Tooth (CMT) peripheral neuropathies, a group of inherited disorders in the muscular dystrophy family that affects peripheral nerves.
- The company's panel sequences all 36 reported CMT disease-causing genes on a reflex basis if the first tier testing for the commonly occurring PMP22 deletions/duplications is negative. The majority of CMT patients have these single-gene mutations so the tiered approach boosts efficiency and saves money.